Merck no longer in talks to buy Revolution Medicines, WSJ reports [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
The talks cooled after the ?two could not come to an agreement on price, the Journal said, citing people familiar with the matter. The newspaper said ?it was ?possible talks could restart or another suitor for Revolution could emerge. Reuters ?could not immediately verify the report. Merck and Revolution Medicines did not immediately respond to Reuters ?requests for comment outside regular business hours. The ?Financial Times reported this month that Merck was in talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. A potential deal with Revolution ?would have given Merck access ?to its experimental drug ?daraxonrasib, which is in late-stage trials and has won a fast-track ?review voucher ?from the U.S. Food and Drug Administration. Revolution has a market capitalization of around $22.7 ?billion, according to LSEG data. (Reporting by Mihika Sharma ?in Bengaluru; Editing by Andrew ?Heavens and David Gregorio)
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective InhibitorGlobeNewswire
- Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 1/23/26 - Form 4
- 1/21/26 - Form 144
- 1/9/26 - Form 4
- RVMD's page on the SEC website